Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGE031 for moderate to severe atopic dermatitis
NL-OMON37121Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ligelizumab in atopic dermatitis (AD) (3 arms), sponsored by Novartis. Primary endpoint: Eczema Area and Severity Index at week 12. Planned start Jun 2012; status: withdrawn.
02
Drugs
ligelizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON37121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37121.